Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
Clinical trial NCT03734029 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03734029
- Sponsor
- Daiichi Sankyo
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-27
- Primary completion
- 2022-01-11
- Enrollment
- 557
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.